nicorandil / Generic mfg. - LARVOL DELTA

Comparison of the Effects of Nicorandil and Sodium Nitroprusside on the Progression of Microvascular Obstruction in the Myocardial Infarction Zone in Rats. (PubMed, Bull Exp Biol Med) - "In a rat in vivo model of regional myocardial ischemia and reperfusion, neither nicorandil nor sodium nitroprusside reduced myocardial infarction size in rats with early no-reflow. Despite the dual mechanism of action of nicorandil (0.2 mg/kg), sodium nitroprusside (60 μg/kg) was more effective in reducing the size of the early no-reflow zone, and a trend toward a decrease in the no-reflow zone was observed at the end of 2‑h reperfusion."

Journal • Preclinical • Cardiovascular • Myocardial Infarction • Myocardial Ischemia • Reperfusion Injury

The Effect of Nicorandil on Rheumatoid Arthritis Patients (clinicaltrials.gov) - P2/3 | N=70 | Recruiting | Sponsor: Ain Shams University | Not yet recruiting ➔ Recruiting

Enrollment open • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology

Preventing Microvascular Obstruction During Primary PCI: Back to a CLEAN Slate? (PubMed, J Am Coll Cardiol) - No abstract available

Journal • Cardiovascular • Myocardial Infarction

Transient ST-segment elevation following coronary artery bypass grafting in a patient with immune thrombocytopenia treated with romiplostim: a case report. (PubMed, Egypt Heart J) - "Transient ST-segment elevation after CABG requires systematic evaluation for both ischemic and non-ischemic causes. In this patient, the combination of inferior ST-segment elevation, PR-segment depression, a documented pericardial friction rub, preserved ventricular function, absence of regional wall motion abnormalities, declining hs-cTnI, elevated inflammatory markers, and spontaneous ECG resolution favored an early postoperative inflammatory process. Romiplostim should be regarded as part of the patient's overall thrombotic-risk profile rather than as a proven direct cause of the transient ECG abnormality."

Journal • Cardiovascular • CNS Disorders • Coronary Artery Disease • Depression • Hematological Disorders • Immune Thrombocytopenic Purpura • Inflammation • Myocardial Infarction • Myocardial Ischemia • Psychiatry • Thrombocytopenia • Thrombocytopenic Purpura • Thrombosis • CRP • TNNI3

A Study to Evaluate the Impact of Pre-procedural Intracoronary Nicorandil Injection to PREVENT reductioN Of decREased TIMI FLOW in Patients Who Undergoing Percutaneous Coronary Intervention for the Coronary Artery Disease (clinicaltrials.gov) - P4 | N=458 | Recruiting | Sponsor: Korea University Anam Hospital | Trial completion date: Dec 2026 ➔ May 2028 | Trial primary completion date: Jul 2026 ➔ May 2027

Trial completion date • Trial primary completion date • Cardiovascular • Coronary Artery Disease

Prospective Study of End Stage Renal Disease Patients With Coronary Artery Disease Treated by Oral Nicorandil (clinicaltrials.gov) - P4 | N=268 | Active, not recruiting | Sponsor: Kumamoto University | Trial completion date: Mar 2026 ➔ Aug 2027

Trial completion date • Cardiovascular • Chronic Kidney Disease • Coronary Artery Disease • Nephrology • Renal Disease

Nicorandil in Atherosclerosis Risk in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - P3 | N=46 | Not yet recruiting | Sponsor: Tanta University

New P3 trial • Atherosclerosis • Cardiovascular • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology

The impact of hyperemic agent selection on the interpretation of invasive coronary microvascular function (ESC 2026) - "In comparison with intracoronary nicorandil, intravenous ATP resulted in a greater decrease in blood pressure and a lower CFR, while IMR, MRR and FFR were comparable. These findings suggest that systemic blood pressure changes induced by hyperaemic agents may influence the interpretation of CFR and should be taken into consideration when assessing coronary microvascular function. In this context, evaluation using MRR, which accounts for haemodynamic conditions, may provide a complementary approach for microvascular assessment."

Cardiovascular • Hypotension

The impact of implantable cardioverter-defibrillator on long-term prognosis of successfully resuscitated patients with vasospastic angina after out-of-hospital cardiac arrest (ESC 2026) - "All 24 survivors received vasospasm-preventive therapy, including calcium channel blockers, nitrates, and/or nicorandil...No statistically significant differences in adverse events were observed between patients with and without ICD implantation. The occurrence of recurrent OHCA in a patient with poor medication adherence despite ICD therapy highlights that device therapy cannot replace optimal medical management. Routine ICD implantation for secondary prevention in patients with VSA-related OHCA may not be warranted; instead, management should be individualized, with strict adherence to optimal vasodilator therapy."

Clinical • Acute Coronary Syndrome • Cardiovascular

Effect of Nicorandil in Type 2 Diabetic Obese Patients (clinicaltrials.gov) - P2 | N=46 | Completed | Sponsor: Tanta University | Recruiting ➔ Completed | Phase classification: P2/3 ➔ P2

Phase classification • Trial completion • Diabetes • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Intravenous Nicorandil in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary PCI: The CLEAN Randomized Clinical Trial. (PubMed, J Am Coll Cardiol) - P4 | "In patients with STEMI undergoing primary percutaneous coronary intervention, adjunctive intravenous nicorandil did not significantly reduce the 12-month primary composite outcome. These findings do not support routine use of intravenous nicorandil in unselected patients with STEMI. (Clinical Efficacy and sAfety of Intravenous Nicorandil; NCT04665648)."

Clinical • Journal • Cardiovascular • Congestive Heart Failure • Heart Failure • Myocardial Infarction • Reperfusion Injury

Reversible cerebral vasoconstriction syndrome with concomitant recurrent subarachnoid hemorrhage and coronary vasospastic angina: A manifestation of systemic vasoconstriction syndrome. (PubMed, Surg Neurol Int) - "Treatment with benidipine and nicorandil was initiated thereafter, and no recurrence of either cardiac or neurological symptoms was observed, with complete resolution of cerebral vasoconstriction on follow-up imaging. Although each condition is potentially reversible, their coexistence supports the concept of systemic vasoconstriction syndrome and underscores the need for vigilance regarding extracranial vascular involvement in patients with RCVS. Early recognition and targeted vasodilator therapy may be essential to prevent serious neurological and cardiovascular complications."

Journal • Cardiovascular • Hematological Disorders • Pain • Subarachnoid Hemorrhage

Safety and Modulation of ABCC9 pathways by nicorandil for the Treatment of Hippocampal Sclerosis of aging: The SMArT–HS Study primary outcome results (CTAD 2026) - No abstract available

Clinical • ABCC9

The Effect of Nicorandil on Rheumatoid Arthritis Patients (clinicaltrials.gov) - P2/3 | N=70 | Not yet recruiting | Sponsor: Ain Shams University

New P2/3 trial • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology

Effects of curcumin and nicorandil on nilotinib-induced QT interval prolongation in rats: A telemetry-based study. (PubMed, Pak J Pharm Sci) - "Nilotinib-induced dose-dependent QTc prolongation was aggravated by curcumin, whereas nicorandil demonstrated a potential protective effect on drug-induced LQTS."

Journal • Preclinical • Cardiovascular • Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia • Oncology • TNFA

Clinical Usefulness of 8-F Sheathless Guiding Catheter for Transradial Approach in Complex Percutaneous Coronary Intervention. (PubMed, JACC Asia) - "Nicorandil administration significantly increased the inner diameter of the radial artery (before: 2.80 ± 0.49 mm, after: 3.00 ± 0.56 mm). TRI with an 8-F sheathless GC might be effective for patients with high bleeding risk who require complex percutaneous coronary intervention procedures."

Journal

Mechanism of Dalbergiae Odoriferae Lignum flavonoids in improving microcirculatory disorders based on neutrophil extracellular traps (PubMed, Zhongguo Zhong Yao Za Zhi) - "Sixty SPF-grade male Sprague-Dawley(SD) rats were randomly divided into a sham operation group, a model group, a nicorandil group(1 mg·kg~(-1)), and low-, medium-, and high-dose DOLF groups(1, 2, and 4 g·kg~(-1), respectively), and were administered the corresponding treatments by gavage for 7 consecutive days...DOLF also alleviated inflammatory cell infiltration and other pathological changes in the heart, liver, lungs, kidneys, and brain; lowered serum levels of CK, CK-MB, AST, ALT, GLU, and Crea; reversed the decreases in microvascular density, diameter, and area, as well as the increases in porosity and blood flow resistance caused by microcirculatory dysfunction; reduced serum levels of TNF-α, IL-1β, and ROS; inhibited NETs formation; and decreased the protein expression of MPO, PAD4, IL-6, and TNF-α in myocardial tissue. These findings suggest that DOLF may improve microcirculatory dysfunction by regulating pathways related to NETs formation, indicating..."

Journal • Inflammation • Oncology • IL1B • IL6 • MPO • TNFA

Combined Effects of Nicorandil and Enhanced External Counterpulsation on Coronary Microcirculation and Exercise Capacity in Patients With Coronary Slow Flow Phenomenon: A Randomized, Controlled, 3-Arm Trial. (PubMed, Clin Ther) - P | "For patients with CSFP, the combination of Nicorandil and EECP improved coronary microvascular function, anginal symptoms, and objective exercise tolerance more effectively than either active monotherapy. The lower observed rate of angina-related re-hospitalization suggests a potential clinical benefit, but this finding should be considered exploratory and requires confirmation in trials adequately powered for clinical outcomes."

Journal • Cardiovascular

Nicorandil to Prevent Contrast-Associated Kidney Injury in High-Risk PCI. (PubMed, Circ Cardiovasc Interv) - "Future studies are warranted to evaluate the long-term clinical benefits of this intervention. URL: https://www.chictr.org.cn; Unique identifier: CTR2200064264."

Journal • Acute Kidney Injury • Nephrology • Renal Disease • CRP • CST3

Clinical outcomes following fractional flow reserve-guided revascularization using nicorandil versus conventional hyperemic agents: insights from the J-PRIDE Registry. (PubMed, Cardiovasc Interv Ther) - "This study aimed to compare clinical outcomes following FFR-guided strategy using nicorandil versus conventional hyperemic agents, such as adenosine or papaverine. A significant interaction was observed only between the effect of nicorandil on TVF and hemodialysis (P for interaction = 0.028). The 1-year TVF rate was comparable between the nicorandil and non-nicorandil groups, supporting the clinical applicability of nicorandil for FFR measurement in clinical practice."

Clinical data • Journal • Cardiovascular • Coronary Artery Disease • Myocardial Infarction

Protective mechanism of nicorandil on myocardial ischemia-reperfusion injury: a multi-omics study highlighting CYP4F5 as a key node. (PubMed, J Cardiothorac Surg) - "Nicorandil may alleviate myocardial I/R injury by regulating CYP4F5-associated metabolites and signaling pathways."

Journal • Cardiovascular • Myocardial Infarction • Myocardial Ischemia • Reperfusion Injury • PPARA

Myocardial Infarction With Nonobstructive Coronary Arteries With Coronary Microvascular Dysfunction Associated With Systemic Sclerosis: Case Report. (PubMed, Case Rep Vasc Med) - "The patient was treated with a calcium-channel blocker and nicorandil...SSc-associated MINOCA, possibly driven by CMD, was diagnosed by comprehensive invasive coronary function testing and CMR. Serial CMR may help to document reversibility of microvascular ischemic injury and guide vasodilator therapy and follow-up."

Journal • Cardiovascular • Immunology • Infectious Disease • Inflammation • Interstitial Lung Disease • Myocardial Infarction • Pain • Pneumonia • Respiratory Diseases • Scleroderma • Systemic Sclerosis • CRP

A retrospective analysis of gastrointestinal adverse events associated with nicorandil using the FDA Adverse Event Reporting System (FAERS) following STROBE guidelines. (PubMed, Medicine (Baltimore)) - "The use of nicorandil was significantly associated with gastrointestinal adverse events. This study assists healthcare professionals in providing appropriate guidance and advice to patients prior to drug administration."

Adverse events • Journal • Observational data • Retrospective data • Colonic Polyps • Gastroenterology

Therapeutic potential of Nicorandil vs Nebivolol in attenuating PKC/P38MAPK signaling via PPARγ/KLOTHO/CREB pathway signaling molecular docking and experimental validation in rat model of unilateral ureteric obstruction. (PubMed, Eur J Pharmacol) - "By targeting interconnected redox, inflammatory, and apoptotic pathways, nebivolol could emerge as a mechanistically therapeutic candidate, offering promise for repurposing in obstructive nephropathy and potentially in broader contexts of chronic kidney disease characterized by complex molecular dysregulation."

Journal • Preclinical • Chronic Kidney Disease • Fibrosis • Immunology • Inflammation • Nephrology • Renal Disease • CAT • KEAP1 • MIR200A • PPARG • SMAD3 • TGFB1

Intracoronary nicorandil improves coronary microcirculatory function after primary PCI in first-episode STEMI: an angiography-derived evaluation using AMR and QFR. (PubMed, Front Cardiovasc Med) - "In this pilot randomized study, intracoronary nicorandil administered during primary PCI was associated with improved angiography-derived surrogate indices of microvascular resistance and epicardial physiology without an observed increase in peri-procedural hemodynamic instability or short-term adverse events. These findings should be interpreted as exploratory and warrant confirmation in larger multicenter studies with longer follow-up and outcome-linked validation."

Journal • Cardiovascular • Hypotension • Myocardial Infarction • TNNI3